111 related articles for article (PubMed ID: 20635971)
21. A multistage-polyepitope vaccine protects against Mycobacterium tuberculosis infection in HLA-DR3 transgenic mice.
Geluk A; van den Eeden SJ; van Meijgaarden KE; Dijkman K; Franken KL; Ottenhoff TH
Vaccine; 2012 Dec; 30(52):7513-21. PubMed ID: 23103299
[TBL] [Abstract][Full Text] [Related]
22. [Dimo-thylidioctyl ammonium bromide-BCG polysaccharide nucleic acid adjuvant enhanced the immunogenicity of a Mycobacterium tuberculosis subunit vaccine].
Song NN; Wang BX; Shi DZ; Fu LF; Luo Y; Yu HJ; Han SB; Jiao L; Qie YQ; Wang HH; Zhang Y; Zhu BD
Zhonghua Jie He He Hu Xi Za Zhi; 2009 Jul; 32(7):513-6. PubMed ID: 19954005
[TBL] [Abstract][Full Text] [Related]
23. GLS/IL-12-modified Mycobacterium smegmatis as a novel anti-tuberculosis immunotherapeutic vaccine.
Yang C; He YL; Zhang L; Xu L; Yi Z; Wang Y; Li N; Zhu D
Int J Tuberc Lung Dis; 2009 Nov; 13(11):1360-6. PubMed ID: 19861007
[TBL] [Abstract][Full Text] [Related]
24. DNA augments antigenicity of mycobacterial DNA-binding protein 1 and confers protection against Mycobacterium tuberculosis infection in mice.
Matsumoto S; Matsumoto M; Umemori K; Ozeki Y; Furugen M; Tatsuo T; Hirayama Y; Yamamoto S; Yamada T; Kobayashi K
J Immunol; 2005 Jul; 175(1):441-9. PubMed ID: 15972678
[TBL] [Abstract][Full Text] [Related]
25. [Preparation of two antigens--Ag85b and HspX of Mycobacterium tuberculosis H37Rv and the effects of their co-administration with adjuvants in mice].
Chen L; Xu M; Du WX; Chen BW; Wang ZY; Wang YJ; Dong N; Su C; Shen XB; Wang GZ
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2009 Aug; 31(4):403-9. PubMed ID: 19771723
[TBL] [Abstract][Full Text] [Related]
26. Nanoparticle conjugation and pulmonary delivery enhance the protective efficacy of Ag85B and CpG against tuberculosis.
Ballester M; Nembrini C; Dhar N; de Titta A; de Piano C; Pasquier M; Simeoni E; van der Vlies AJ; McKinney JD; Hubbell JA; Swartz MA
Vaccine; 2011 Sep; 29(40):6959-66. PubMed ID: 21787826
[TBL] [Abstract][Full Text] [Related]
27. Targeting of immunostimulatory DNA cures experimental visceral leishmaniasis through nitric oxide up-regulation and T cell activation.
Datta N; Mukherjee S; Das L; Das PK
Eur J Immunol; 2003 Jun; 33(6):1508-18. PubMed ID: 12778468
[TBL] [Abstract][Full Text] [Related]
28. Liposomes based on dimethyldioctadecylammonium promote a depot effect and enhance immunogenicity of soluble antigen.
Henriksen-Lacey M; Bramwell VW; Christensen D; Agger EM; Andersen P; Perrie Y
J Control Release; 2010 Mar; 142(2):180-6. PubMed ID: 19874860
[TBL] [Abstract][Full Text] [Related]
29. Immunotherapeutic potential of N-formylated peptides of ESAT-6 and glutamine synthetase in experimental tuberculosis.
Mir SA; Sharma S
Int Immunopharmacol; 2014 Feb; 18(2):298-303. PubMed ID: 24369314
[TBL] [Abstract][Full Text] [Related]
30. Transfer factors as immunotherapy and supplement of chemotherapy in experimental pulmonary tuberculosis.
Fabre RA; Pérez TM; Aguilar LD; Rangel MJ; Estrada-Garcìa I; Hernández-Pando R; Estrada Parra S
Clin Exp Immunol; 2004 May; 136(2):215-23. PubMed ID: 15086383
[TBL] [Abstract][Full Text] [Related]
31. Comparative evaluation of intranasal and subcutaneous route of immunization for development of mucosal vaccine against experimental tuberculosis.
Giri PK; Sable SB; Verma I; Khuller GK
FEMS Immunol Med Microbiol; 2005 Jul; 45(1):87-93. PubMed ID: 15985227
[TBL] [Abstract][Full Text] [Related]
32. Multicomponent antituberculous subunit vaccine based on immunodominant antigens of Mycobacterium tuberculosis.
Sable SB; Verma I; Khuller GK
Vaccine; 2005 Jul; 23(32):4175-84. PubMed ID: 15923065
[TBL] [Abstract][Full Text] [Related]
33. Safety and efficacy of nasal application of CpG oligodeoxynucleotide as a mucosal adjuvant.
Kodama S; Abe N; Hirano T; Suzuki M
Laryngoscope; 2006 Feb; 116(2):331-5. PubMed ID: 16467729
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of immunogenicity and protective efficacy against Mycobacterium tuberculosis infection elicited by recombinant Mycobacterium bovis BCG expressing human Interleukin-12p70 and Early Secretory Antigen Target-6 fusion protein.
Deng Y; Bao L; Yang X
Microbiol Immunol; 2011 Nov; 55(11):798-808. PubMed ID: 21831202
[TBL] [Abstract][Full Text] [Related]
35. The T cell response to secreted antigens of Mycobacterium tuberculosis.
Andersen P
Immunobiology; 1994 Oct; 191(4-5):537-47. PubMed ID: 7713568
[TBL] [Abstract][Full Text] [Related]
36. Enhanced immunoprotective potential of Mycobacterium tuberculosis Ag85 complex protein based vaccine against airway Mycobacterium tuberculosis challenge following intranasal administration.
Giri PK; Verma I; Khuller GK
FEMS Immunol Med Microbiol; 2006 Jul; 47(2):233-41. PubMed ID: 16831210
[TBL] [Abstract][Full Text] [Related]
37. Specificity and efficacy of dendritic cell-based vaccination against tuberculosis with complex mycobacterial antigens in a mouse model.
Rubakova E; Petrovskaya S; Pichugin A; Khlebnikov V; McMurray D; Kondratieva E; Baturina I; Kondratieva T; Apt A
Tuberculosis (Edinb); 2007 Mar; 87(2):134-44. PubMed ID: 17011827
[TBL] [Abstract][Full Text] [Related]
38. Treatment of multi-drug-resistant tuberculosis in mice with DNA vaccines alone or in combination with chemotherapeutic drugs.
Liang Y; Wu X; Zhang J; Yang Y; Wang L; Bai X; Yu Q; Li N; Li Z
Scand J Immunol; 2011 Jul; 74(1):42-6. PubMed ID: 21352251
[TBL] [Abstract][Full Text] [Related]
39. Therapeutic efficacy of a tuberculosis DNA vaccine encoding heat shock protein 65 of Mycobacterium tuberculosis and the human interleukin 2 fusion gene.
Changhong S; Hai Z; Limei W; Jiaze A; Li X; Tingfen Z; Zhikai X; Yong Z
Tuberculosis (Edinb); 2009 Jan; 89(1):54-61. PubMed ID: 19056317
[TBL] [Abstract][Full Text] [Related]
40. Immunization with a mycobacterial lipid vaccine improves pulmonary pathology in the guinea pig model of tuberculosis.
Dascher CC; Hiromatsu K; Xiong X; Morehouse C; Watts G; Liu G; McMurray DN; LeClair KP; Porcelli SA; Brenner MB
Int Immunol; 2003 Aug; 15(8):915-25. PubMed ID: 12882829
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
